<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40984804</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1797</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nephrology (Carlton, Vic.)</Title><ISOAbbreviation>Nephrology (Carlton)</ISOAbbreviation></Journal><ArticleTitle>Preventive Efficacy of Oxygenation on Contrast-Associated Acute Kidney Injury in Chronic Kidney Disease (stages 3-5) Patients Undergoing Elective Coronary Angiography &#xb1; Revascularisation: An Open Label Bicentric Randomised Controlled Trial.</ArticleTitle><Pagination><StartPage>e70122</StartPage><MedlinePgn>e70122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nep.70122</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Contrast-associated acute kidney injury (CA-AKI) has higher mortality in coronary artery disease (CAD) with chronic kidney disease (CKD), undergoing coronary angiography &#xb1; revascularisation (CAG&#x2009;&#xb1;&#x2009;R). We conducted a clinical superiority trial with dichotomous outcomes to evaluate the impact of renal hypoxia mitigation with oxygen therapy (OT) on CA-AKI incidence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">CKD stages 3-5 patients undergoing CAG&#x2009;&#xb1;&#x2009;R were assigned to the OT group (OTG) and the control therapy group (CTG). CTG received hydration only, whereas OTG received 2&#x2009;L/min of pure oxygen in addition to hydration. The primary endpoint was the incidence of CA-AKI at 48&#x2009;h. Secondary endpoints included patient and renal survival (doubling of serum creatinine or dialysis dependency) at 30&#x2009;days, as well as intervention complications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 395 patients, 321 patients qualified for the per-protocol analysis (OTG: 160 and CTG: 161). CA-AKI incidence was 5.6%, and OTG observed an effective prevention (1.25% vs. 9.93%, CTG, p&#x2009;=&#x2009;0.004). Renal and patient survival at 30&#x2009;days was 100%. Three CTG patients required dialysis and were dialysis-independent at 30&#x2009;days. The risk of CA-AKI incidence was high among ages &gt;&#x2009;65&#x2009;years (p&#x2009;=&#x2009;0.007), previous acute myocardial infarction (p&#x2009;=&#x2009;0.02), CKD stage-3 (p&#x2009;=&#x2009;0.01) and avoidance of OT use (p&#x2009;=&#x2009;0.02). OTG had a favourable serum creatinine trend (p&#x2009;=&#x2009;0.05). Absolute risk reduction of CA-AKI with OT was 8.7%, and the number needed to treat was 12. Interventional complications were zero.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Oxygen supplementation and saline hydration effectively prevented CA-AKI in CKD stages 3-5 patients undergoing elective CAG&#x2009;&#xb1;&#x2009;R. Hence, oxygen therapy should be a standard CA-AKI protective strategy during CAG&#x2009;&#xb1;&#x2009;R and radiocontrast-related procedures.</AbstractText><CopyrightInformation>&#xa9; 2025 Asian Pacific Society of Nephrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Inderpreet Singh</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Armed Forces Medical College, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murari</LastName><ForeName>Tomala</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, Armed Forces Medical College, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dogra</LastName><ForeName>Pavitra Manu</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-0582-3845</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Army Hospital (R&amp;R), Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ananthakrishnan</LastName><ForeName>Ramamoorthy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Army Institute of Cardiothoracic Sciences, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhillon</LastName><ForeName>Gurmanbir Singh</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Armed Forces Medical College, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasvi</LastName><ForeName>Jayaraj</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0998-0776</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Armed Forces Medical College, Pune, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Nephrology (Carlton)</MedlineTA><NlmUniqueID>9615568</NlmUniqueID><ISSNLinking>1320-5358</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="Y">Contrast Media</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="Y">Coronary Angiography</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="Y">Oxygen Inhalation Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009204" MajorTopicYN="Y">Myocardial Revascularization</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute kidney injury</Keyword><Keyword MajorTopicYN="N">contrast agents</Keyword><Keyword MajorTopicYN="N">contrast nephropathy</Keyword><Keyword MajorTopicYN="N">coronary angiography</Keyword><Keyword MajorTopicYN="N">oxygenation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40984804</ArticleId><ArticleId IdType="doi">10.1111/nep.70122</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>T. G. Gleeson and S. Bulugahapitiya, &#x201c;Contrast&#x2010;Induced Nephropathy,&#x201d; AJR. American Journal of Roentgenology 183, no. 6 (2004): 1673&#x2013;1689, https://doi.org/10.2214/ajr.183.6.01831673.</Citation></Reference><Reference><Citation>R. W. Katzberg and C. Haller, &#x201c;Contrast&#x2010;Induced Nephrotoxicity: Clinical Landscape,&#x201d; Kidney International. Supplement 69, no. 100 (2006): S3&#x2013;S7, https://doi.org/10.1038/sj.ki.5000366.</Citation></Reference><Reference><Citation>J. S. McDonald, R. J. McDonald, J. Comin, et&#xa0;al., &#x201c;Frequency of Acute Kidney Injury Following Intravenous Contrast Medium Administration: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Radiology 267, no. 1 (2013): 119&#x2013;128, https://doi.org/10.1148/radiol.12121460.</Citation></Reference><Reference><Citation>S. D. Weisbord, M. K. Mor, A. L. Resnick, et&#xa0;al., &#x201c;Prevention, Incidence, and Outcomes of Contrast&#x2010;Induced Acute Kidney Injury,&#x201d; Archives of Internal Medicine 168, no. 12 (2008): 1325&#x2013;1332, https://doi.org/10.1001/archinte.168.12.1325.</Citation></Reference><Reference><Citation>Kidney Disease Improving Global Outcomes (KDIGO), &#x201c;Clinical Practice Guideline for Acute Kidney Injury,&#x201d; Kidney International. Supplement 2 (2012): 1&#x2013;138.</Citation></Reference><Reference><Citation>R. Mehran, G. D. Dangas, and S. D. Weisbord, &#x201c;Contrast&#x2010;Associated Acute Kidney Injury,&#x201d; New England Journal of Medicine 380, no. 22 (2019): 2146&#x2013;2155, https://doi.org/10.1056/NEJMra1805256.</Citation></Reference><Reference><Citation>R. Mehran and E. Nikolsky, &#x201c;Contrast&#x2010;Induced Nephropathy: Definition, Epidemiology, and Patients at Risk,&#x201d; Kidney International. Supplement 69, no. 100 (2006): S11&#x2013;S15, https://doi.org/10.1038/sj.ki.5000368.</Citation></Reference><Reference><Citation>P. A. McCullough and K. R. Sandberg, &#x201c;Epidemiology of Contrast&#x2010;Induced Nephropathy,&#x201d; Reviews in Cardiovascular Medicine 4, no. Suppl 5 (2003): S3&#x2013;S9.</Citation></Reference><Reference><Citation>K. Przyklenk and P. Whittaker, &#x201c;Remote Ischemic Preconditioning: Current Knowledge, Unresolved Questions, and Future Priorities,&#x201d; Journal of Cardiovascular Pharmacology and Therapeutics 16, no. 3&#x2013;4 (2011): 255&#x2013;259, https://doi.org/10.1177/1074248411409040.</Citation></Reference><Reference><Citation>S. N. Heyman, M. Brezis, F. H. Epstein, K. Spokes, P. Silva, and S. Rosen, &#x201c;Early Renal Medullary Hypoxic Injury From Radiocontrast and Indomethacin,&#x201d; Kidney International 40, no. 4 (1991): 632&#x2013;642, https://doi.org/10.1038/ki.1991.255.</Citation></Reference><Reference><Citation>P. Whittaker and K. Przyklenk, &#x201c;Remote&#x2010;Conditioning Ischemia Provides a Potential Approach to Mitigate Contrast Medium&#x2010;Induced Reduction in Kidney Function: A Retrospective Observational Cohort Study,&#x201d; Cardiology 119, no. 3 (2011): 145&#x2013;150, https://doi.org/10.1159/000330930.</Citation></Reference><Reference><Citation>R. Solomon, C. Werner, D. Mann, J. D'Elia, and P. Silva, &#x201c;Effects of Saline, Mannitol, and Furosemide on Acute Decreases in Renal Function Induced by Radiocontrast Agents,&#x201d; New England Journal of Medicine 331, no. 21 (1994): 1416&#x2013;1420, https://doi.org/10.1056/NEJM199411243312104.</Citation></Reference><Reference><Citation>E. C. Nijssen, R. J. Rennenberg, P. J. Nelemans, et&#xa0;al., &#x201c;Prophylactic Hydration to Protect Renal Function From Intravascular Iodinated Contrast Material in Patients at High Risk of Contrast&#x2010;Induced Nephropathy (AMACING): A Prospective, Randomised, Phase 3, Controlled, Open&#x2010;Label, Non&#x2010;Inferiority Trial,&#x201d; Lancet 389, no. 10076 (2017): 1312&#x2013;1322, https://doi.org/10.1016/S0140&#x2010;6736(17)30057&#x2010;0.</Citation></Reference><Reference><Citation>P. Liss, A. Nygren, U. Erikson, and H. R. Ulfendahl, &#x201c;Injection of Low and Iso&#x2010;Osmolar Contrast Medium Decreases Oxygen Tension in the Renal Medulla,&#x201d; Kidney International 53, no. 3 (1998): 698&#x2013;702, https://doi.org/10.1046/j.1523&#x2010;1755.1998.00811.x.</Citation></Reference><Reference><Citation>A. Sato, T. Hoshi, and K. Aonuma, &#x201c;No Prophylaxis Is Non&#x2010;Inferior and Cost&#x2010;Saving to Prophylactic Intravenous Hydration in Preventing Contrast&#x2010;Induced Nephropathy on Requiring Iodinated Contrast Material Administration,&#x201d; Journal of Thoracic Disease 9, no. 6 (2017): 1440&#x2013;1442, https://doi.org/10.21037/jtd.2017.05.59.</Citation></Reference><Reference><Citation>K. Nash, A. Hafeez, and S. Hou, &#x201c;Hospital&#x2010;Acquired Renal Insufficiency,&#x201d; American Journal of Kidney Diseases 39, no. 5 (2002): 930&#x2013;936, https://doi.org/10.1053/ajkd.2002.32766.</Citation></Reference><Reference><Citation>J. Cerd&#xe1;, N. Lameire, P. Eggers, et&#xa0;al., &#x201c;Epidemiology of Acute Kidney Injury,&#x201d; Clinical Journal of the American Society of Nephrology 3, no. 3 (2008): 881&#x2013;886, https://doi.org/10.2215/CJN.04961107.</Citation></Reference><Reference><Citation>P. A. McCullough, R. Wolyn, L. L. Rocher, R. N. Levin, and W. W. O'Neill, &#x201c;Acute Renal Failure After Coronary Intervention: Incidence, Risk Factors, and Relationship to Mortality,&#x201d; American Journal of Medicine 103, no. 5 (1997): 368&#x2013;375, https://doi.org/10.1016/s0002&#x2010;9343(97)00150&#x2010;2.</Citation></Reference><Reference><Citation>R. Mehran, E. D. Aymong, E. Nikolsky, et&#xa0;al., &#x201c;A Simple Risk Score for Prediction of Contrast&#x2010;Induced Nephropathy After Percutaneous Coronary Intervention: Development and Initial Validation,&#x201d; Journal of the American College of Cardiology 44, no. 7 (2004): 1393&#x2013;1399, https://doi.org/10.1016/j.jacc.2004.06.068.</Citation></Reference><Reference><Citation>E. M. Lautin, N. J. Freeman, A. H. Schoenfeld, et&#xa0;al., &#x201c;Radiocontrast&#x2010;Associated Renal Dysfunction: A Comparison of Lower&#x2010;Osmolality and Conventional High&#x2010;Osmolality Contrast Media,&#x201d; AJR American Journal of Roentgenology 157, no. 1 (1991): 59&#x2013;65, https://doi.org/10.2214/ajr.157.1.2048540.</Citation></Reference><Reference><Citation>H. Sekiguchi, Y. Ajiro, Y. Uchida, et&#xa0;al., &#x201c;Contrast&#x2010;Induced Nephropathy and Oxygen Pretreatment in Patients With Impaired Renal Function,&#x201d; Kidney International Reports 3, no. 1 (2017): 65&#x2013;72, https://doi.org/10.1016/j.ekir.2017.08.002.</Citation></Reference><Reference><Citation>F. Minoo, M. Lessan&#x2010;Pezeshki, A. Firouzi, S. Nikfarjam, S. M. Gatmiri, and E. Ramezanzade, &#x201c;Prevention of Contrast&#x2010;Induced Nephropathy With Oxygen Supplementation: A Randomized Controlled Trial,&#x201d; Iranian Journal of Kidney Diseases 10, no. 5 (2016): 291&#x2013;298.</Citation></Reference><Reference><Citation>H. Sekiguchi, Y. Ajiro, Y. Uchida, et&#xa0;al., &#x201c;Oxygen Preconditioning Prevents Contrast&#x2010;Induced Nephropathy in Patients With Chronic Kidney Disease: Option CIN&#x2010;CKD Randomized Trial,&#x201d; European Heart Journal Supplements 34, no. Supplement 1 (2013): S795, https://doi.org/10.1093/eurheartj/eht309.P4298.</Citation></Reference><Reference><Citation>H. Sekiguchi, Y. Ajiro, Y. Uchida, et&#xa0;al., &#x201c;Oxygen Pre&#x2010;Conditioning Prevents Contrast&#x2010;Induced Nephropathy (OPtion CIN Study),&#x201d; Journal of the American College of Cardiology 62, no. 2 (2013): 162&#x2013;163, https://doi.org/10.1016/j.jacc.2013.04.012.</Citation></Reference><Reference><Citation>A. A. Emara, A. G. Shalaby, M. M. Hanna, and W. F. Abd El Aziz, &#x201c;Effect of Oxygen Therapy on the Incidence of Contrast&#x2010;Induced Nephropathy in Patients Undergoing Coronary Angiography,&#x201d; Menoufia Medical Journal 31, no. 2 (2018): 365&#x2013;371, https://doi.org/10.4103/mmj.mmj_376_15.</Citation></Reference><Reference><Citation>T. Z. Ahimahalle, A. Amirfarhangi, M. Jabbari, A. Jenabi, H. Bagherzadegan, and G. Noghabaei, &#x201c;Impact of Oxygen Therapy to Ameliorate Contrast&#x2010;Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Emergency Angiography; a Double&#x2010;Blinded Clinical Trial,&#x201d; Journal of Renal Injury Prevention 8, no. 4 (2019): 283&#x2013;288, https://doi.org/10.15171/jrip.2019.52.</Citation></Reference><Reference><Citation>M. Ye, W. Lin, J. Zheng, and S. Lin, &#x201c;N&#x2010;Acetylcysteine for Chronic Kidney Disease: A Systematic Review and Meta&#x2010;Analysis,&#x201d; American Journal of Translational Research 13, no. 4 (2021): 2472&#x2013;2485.</Citation></Reference><Reference><Citation>A. H. Chiu, C. J. Wang, Y. L. Lin, C. L. Wang, and T. I. Chiang, &#x201c;N&#x2010;Acetylcysteine Alleviates the Progression of Chronic Kidney Disease: A Three&#x2010;Year Cohort Study,&#x201d; Medicina (Kaunas, Lithuania) 59, no. 11 (2023): 1983, https://doi.org/10.3390/medicina59111983.</Citation></Reference><Reference><Citation>E. Y. Hern&#xe1;ndez&#x2010;Cruz, O. E. Aparicio&#x2010;Trejo, F. A. Hammami, et&#xa0;al., &#x201c;N&#x2010;Acetylcysteine in Kidney Disease: Molecular Mechanisms, Pharmacokinetics, and Clinical Effectiveness,&#x201d; Kidney International Reports 9, no. 10 (2024): 2883&#x2013;2903, https://doi.org/10.1016/j.ekir.2024.07.020.</Citation></Reference><Reference><Citation>D. Stub, K. Smith, S. Bernard, et&#xa0;al., &#x201c;Air Versus Oxygen in ST&#x2010;Segment&#x2010;Elevation Myocardial Infarction,&#x201d; Circulation 131, no. 24 (2015): 2143&#x2013;2150, https://doi.org/10.1161/CIRCULATIONAHA.114.014494.</Citation></Reference><Reference><Citation>T. Minor, M. Sitzia, and F. Dombrowski, &#x201c;Kidney Transplantation From Non&#x2010;Heart&#x2010;Beating Donors After Oxygenated Low&#x2010;Flow Machine Perfusion Preservation With Histidine&#x2010;Tryptophan&#x2010;Ketoglutarate Solution,&#x201d; Transplant International 17, no. 11 (2005): 707&#x2013;712, https://doi.org/10.1007/s00147&#x2010;004&#x2010;0795&#x2010;3.</Citation></Reference><Reference><Citation>S. A. Hosgood, R. J. Brown, and M. L. Nicholson, &#x201c;Advances in Kidney Preservation Techniques and Their Application in Clinical Practice,&#x201d; Transplantation 105, no. 11 (2021): e202&#x2013;e214, https://doi.org/10.1097/TP.0000000000003679.</Citation></Reference><Reference><Citation>B. Velayudhan and M. Idhrees, &#x201c;COVID&#x2010;19: An Indian Perspective,&#x201d; Journal of Cardiac Surgery 36, no. 5 (2021): 1713&#x2013;1716, https://doi.org/10.1111/jocs.15203.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>